Trial Profile
A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jun 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shire
- 05 Aug 2010 Shire plc media release presents published results of study showing that once-daily lisdexamfetamine capsules provide significant efficacy at 2 hours through 14 hours after administration, in adults with ADHD.
- 24 Jul 2010 Results published in Behavioral and Brain Functions, as reported in Shire Plc media release, show that once-daily lisdexamfetamine capsules provide significant efficacy at 2 hours through 14 hours after administration, in adults with ADHD.
- 24 Jun 2010 Primary endpoint 'Permanent Product Measure of Performance' has been met.